1356332-97-2

Upstream product

• 1356332-28-9 2,3-di-p-tolyl-5,6,7,8-tetrahydropyrido[2,3-b]pyrazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 452-58-4 2,3-Diaminopyridine 
• 3457-48-5 1,2-di(4-methylphenyl)-1,2-ethanedione 
• 1356332-96-1 2,3-di-p-tolyl-5,6-dihydropyrido[2,3-b]pyrazine 

Downstream Products

• 1356332-98-3 7,8-dihydroxy-2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-carboxylic acid tert-butyl ester 
• 1356332-99-4 tert‐butyl 7,8‐bis(acetyloxy)‐2,3‐bis(4‐methylphenyl)‐5H,6H,7H,8H‐pyrido[2,3‐b]pyrazine‐5‐carboxylate 
• 1356333-00-0 7‐(acetyloxy)‐2,3‐bis(4‐methylphenyl)‐5H,6H,7H,8H‐pyrido[2,3‐b]pyrazin‐8‐yl acetate 
• 1356333-01-1 ethyl 7‐[7,8‐bis(acetyloxy)‐2,3‐bis(4‐methylphenyl)‐5H,6H,7H,8H‐pyrido[2,3‐b]pyrazin‐5‐yl]heptanoate 
• 1447306-88-8 rac-tert-butyl 2-thioxo-7,8-di-p-tolyl-3a,4-dihydro-[1,3]dioxolo[4',5':4,5]pyrido[2,3-b]pyrazine-5(9bH)-carboxylate 
• 1447306-89-9 rac-tert-butyl 7-hydroxy-2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazine-5(6H)-carboxylate 
• 1447306-90-2 tert-butyl 7-acetoxy-2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazine-5(6H)-carboxylate 
• 1447307-14-3 tert-butyl 7-(piperidin-1-yl)-2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazine-5(6H)-carboxylate 
• 1447306-91-3 7-(piperidin-1-yl)-2,3-di-p-tolyl-5,6,7,8-tetrahydropyrido[2,3-b]pyrazine 
• 1447306-92-4 ethyl 7-(7-(piperidin-1-yl)-2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoate 
• 1447305-23-8 7-(7-(piperidin-1-yl)-2,3-di-p-tolyl-7,8-dihydropyrido[2,3-b]pyrazin-5(6H)-yl)heptanoic acid 
• 1447450-45-4 rac-2,3-di-p-tolyl-5,6,7,8-tetrahydropyrido[2,3-b]pyrazin-7-ol 
• 1447450-46-5 rac-5-(hex-5-enyl)-2,3-di-p-tolyl-5,6,7,8-tetrahydropyrido[2,3-b]pyrazin-7-ol 
• 1447450-47-6 rac-(E)-5-(6-(1H-tetrazol-5-yl)hex-5-enyl)-2,3-di-p-tolyl-5,6,7,8-tetrahydropyrido[2,3-b]pyrazin-7-ol 

Relevant academic research and scientific papers

Ip receptor agonist heterocyclic compounds

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various or

FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) AND RELATED DISORDERS

The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Formula (I):

FUSED PIPERIDINES AS IP RECEPTOR AGONISTS FOR THE TREATMENT OF PAH AND RELATED DISORDERS

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.

IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS

The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.